




RealRate

PHARMACEUTICAL 2013

Puramed Bioscience Inc
Rank 204 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Puramed Bioscience Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Puramed Bioscience Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Puramed Bioscience Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 134% points.

The company's Economic Capital Ratio, given in the ranking table, is 31%, being 189% points below the market average of 220%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	209	Assets	400
Cost of Goods Sold	0	Liabilities	1,467
Intangible Assets	86	Expenses	2,042
Liabilities, Current	1,467	Revenues	693
Liabilities, Non-Current	0	Stockholders Equity	-1,066
Other Assets	98	Net Income	-1,721
Other Compr. Net Income	0	Comprehensive Net Income	-1,721
Other Expenses	1,843	BaseVar	2,487
Other Liabilities	0	ECR before LimitedLiability	-433%
Other Net Income	-373	Economic Capital Ratio	31%
Other Revenues	693		
Property and Equipment	7.2		
Research and Development	18		
Selling, General and Administrative Expense	181		